Healthcare is a technologically driven industry and some of those advances are apparent in the products now reaching consumers directly.
From the convenience of home, consumers can order tests that allow them to gain insight about what their genes or their microbiomes can tell them about their health or the risk of developing a particular disease. In the realm of substance abuse, digital technologies are emerging to supplement more traditional approaches to managing addiction. We learned about some the progress of these technologies and more last week during What’s Hot in Bay Area Biotech, Xconomy’s annual look at life science innovation in the San Francisco area.
While some of the technologies discussed during the event are already in the hands of patients and consumers, others will still need years of additional research and testing before they reach the market. For example, blood tests that could detect the early signs of cancer in an apparently healthy person are a decade or more away. In the meantime, we have photos of some of the players involved in developing these technologies and more from our event at UCSF Mission Bay, courtesy of Michael Drew Photography.
We’d like to thank the sponsors, whose support made What’s Hot in Bay Area Biotech possible, including our host, QB3; silver sponsor Biocom; reception sponsors Chrysalis Biomedical Advisors and Next Interactions. And last but not least, a thank you to our audience, who engaged with the speakers and their ideas.
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
